An Update on the Role of Nitrofurans in the Management of Urinary Tract Infections

Guay, D.R.
February 2001
Drugs;Feb2001, Vol. 61 Issue 3, p353
Academic Journal
There have been few recent reviews of the nitrofurans in the literature, and none include recently available data on the use of nitrofurazone (nitrofural) in the prevention of catheter-associated urinary tract infection (CAUTI). Nitrofurazone and nitrofurantoin are the only nitrofurans that have become established in clinical use in the 20th century. These 2 nitrofurans have remained clinically useful against a wide spectrum of Gram-positive and Gram-negative bacteria, including many strains of common urinary tract pathogens. Today, the primary use of nitrofurantoin is as an oral antibacterial treatment for genitourinary infections. Nitrofurazone is primarily used as a topical antibacterial agent in burns and skin grafts and recently was approved for the prophylaxis of CAUTI. The recent development of a nitrofurazone-impregnated catheter as a novel modality in the prevention of CAUTI reflects a renewed interest in the effectiveness of nitrofurans. In an era when concern about bacterial resistance to many anti-infective agents is growing, the nitrofurans have continued to be active against organisms that have developed resistance to antibacterials. The presence of multiple mechanisms of action for the nitrofurans might be expected to reduce the ability of bacteria to develop resistance. Considering that an emergence of resistance to the nitrofurans has not appreciably occurred after several decades of clinical use, the nitrofurans may be unique among common antibacterial agents in this regard.


Related Articles

  • Study of four empiric therapies for UTI: A quinolone is most cost-effective.  // Modern Medicine;Dec96, Vol. 64 Issue 12, p26 

    Discusses a study conducted by physician Michael Rosenberg and colleagues on the cost-effectiveness of four empiric therapies for uncomplicated urinary tract infection. Costs of evaluation, treatment, and outcomes; Antimicrobial sensitivity to Escherichia coli.

  • Is 3-day better than 10-day course for antibiotics for returning UTIs?  // Urology Times;Aug96, Vol. 24 Issue 8, p29 

    Discusses a May 1996 `Consumer Reports' article on the effectiveness of ten-day antibiotic therapy for recurrent urinary tract infections.

  • Antibiotics for UTIs clear FDA hurdles.  // Urology Times;Feb97, Vol. 25 Issue 2, p40 

    Cites antibiotics for urinary tract infections (UTI) which have received the approval of the US Food and Drug Administration. Fosfomycin tromethamine (Monrurol); Levoflaxin (Levaquin) from Ortho-McNeil Pharmaceuticals; New indications for ciprofloxacin (Cipro) antibacterial therapy from Bayer Corp.

  • Nitrofurantoin.  // Reactions Weekly;2/28/2009, Issue 1241, p32 

    The article describes the case of a 57-year-old woman who experienced acute interstitial nephritis and hepatitis following treatment with nitrofurantoin for a urinary tract infection. The patient developed fever and was admitted to hospital. Increases in liver enzyme, mild eosinophilia and...

  • Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? B. J. Knottnerus; S. Nys; G. ter Riet; G. Donker; S. E. Geerlings; E. Stobberingh // Journal of Antimicrobial Chemotherapy (JAC);Aug2008, Vol. 62 Issue 2, p356 

    Background Uncomplicated urinary tract infections (UTIs) are common among female patients. According to the national guidelines of the Dutch College of General Practitioners (GPs), the drugs of first and second choice as therapy for UTIs are nitrofurantoin and trimethoprim with resistance...

  • Urinary Infection Prophylaxis in Women. Ronald, Allan R.; Harding, Goferey K.M. // Annals of Internal Medicine;Feb81, Vol. 94 Issue 2, p268 

    Comments on the recurrent urinary infection associated with chemoprophylaxis, an antibacterial therapy. Requirement before administering chemoprophylaxis; Agents that have been shown effective in prospective comparative studies for the prevention of infection in most women; Details on the...

  • Single-dose UTI agent promising in trials.  // Urology Times;May99, Vol. 27 Issue 5, p3 

    Reports on the success of the preliminary tests on the potency of liposomal amikacin in preventing the recurrence of complicated urinary tract infections (UTI).

  • Three-day and ten-day chemotherapy for urinary tract infections in general practice. Charlton, C.A.C.; Crowther, A.; Davies, J.G.; Dynes, J.; Haward, A.W.A.; Mann, P.G.; Rye, S. // British Medical Journal;1/17/1976, Vol. 1 Issue 6002, p124 

    Examines the lenght of course for chemotherapy in treating urinary tract infections within general practice. Use of antibiotic for the treatment of infection; Symptoms of the disease; Complication of the disease.

  • Nitrofurantoin-Induced Hepatotoxicity Mediated by CD8+ T Cells. Kelly, Brendan D.; Heneghan, Michael A.; Bennani, Fadel; Connolly, Charles E.; O'Gorman, Thomas A. // American Journal of Gastroenterology;May1998, Vol. 93 Issue 5, p819 

    Nitrofurantoin is a synthetic nitrofuran commonly used for the treatment and prophylaxis of urinary tract infections. We describe the case of a 75-yr-old woman who was taking nitrofurantoin as prophylaxis against recurrent urinary tract infections, and who subsequently developed pulmonary and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics